ARTICLE | Clinical News
Genitope down on MyVax news
July 27, 2005 12:44 AM UTC
On Tuesday, GTOP fell $3.41 (28%) to $8.80 after reporting that its MyVax vaccine has not yet met the primary endpoint of progression-free survival in a Phase III trial to treat follicular non-Hodgkin's lymphoma (NHL). The DSMB did not disclose data from its first interim analysis but recommended that the trial continue. The next interim analysis is expected in mid-2006. ...